Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen drug portfolio — 45 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Status
Public
HQ
225 Binney Street, Cambridge, MA 02142, US
Employees
7,534
Programs
31
Drugs
45
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

Biogen pipeline

Portfolio lens on 45 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Biogen drug portfolio — 45 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

45 compounds

  1. acyclovir sodium

    US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  2. anti-

    Development asset linked to Biogen in public FDA and regional records.

  3. antibody

    Development asset linked to Biogen in public FDA and regional records.

  4. bardoxolone methyl

    Development asset linked to Biogen in public FDA and regional records. Molecular target: Inhibitor of nuclear factor kappa-B kinase subunit beta.

    Target
    Inhibitor of nuclear factor kappa-B kinase subunit beta
    Mechanism
    Keap1/Nrf2 inhibitor

  5. capsule

    Development asset linked to Biogen in public FDA and regional records.

  6. capsules

    Development asset linked to Biogen in public FDA and regional records.

  7. carbamazepine

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  8. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  9. cetirizine

    Development asset linked to Biogen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  11. control

    Development asset linked to Biogen in public FDA and regional records.

  12. daclizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-2 receptor.

    Target
    Interleukin-2 receptor
    Mechanism
    Interleukin-2 receptor inhibitor

  13. desirudin

    Blood and blood forming organs (B01)

    Blood and blood forming organs (B01) compound in Biogen's portfolio. Molecular target: Prothrombin.

    Target
    Prothrombin
    Mechanism
    Thrombin inhibitor

  14. desloratadine

    Respiratory system (R01)

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  15. dimethyl

    Development asset linked to Biogen in public FDA and regional records.

  16. dimethyl fumarate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.

    Target
    Kelch-like ECH-associated protein 1
    Mechanism
    Kelch-like ECH-associated protein 1 inhibitor

  17. diphenhydramine

    Development asset linked to Biogen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  18. diphenhydramine hydrochloride

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  19. diroximel fumarate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.

    Target
    Kelch-like ECH-associated protein 1
    Mechanism
    Kelch-like ECH-associated protein 1 inhibitor

  20. famotidine

    US regulatory status: approved. Molecular target: Histamine H2 receptor.

    Target
    Histamine H2 receptor
    Mechanism
    Histamine H2 receptor antagonist

  21. fexofenadine

    Development asset linked to Biogen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  22. formulation

    Development asset linked to Biogen in public FDA and regional records.

  23. hema-

    Development asset linked to Biogen in public FDA and regional records.

  24. infusion

    Development asset linked to Biogen in public FDA and regional records.

  25. injection

    Development asset linked to Biogen in public FDA and regional records.

  26. interferon beta-1a

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  28. loratadine

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  29. matching

    Development asset linked to Biogen in public FDA and regional records.

  30. methylprednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  31. natalizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Integrin alpha-4/beta-1.

    Target
    Integrin alpha-4/beta-1
    Mechanism
    Integrin alpha-4/beta-7 inhibitor

  32. nusinersen

    Musculo-skeletal system (M09)

    Musculo-skeletal system (M09) compound in Biogen's portfolio.

  33. nusinersen sodium

    US regulatory status: approved. Molecular target: SMN2 pre-mRNA.

    Target
    SMN2 pre-mRNA
    Mechanism
    SMN2 pre-mRNA positive modulator

  34. paracetamol

    Development asset linked to Biogen in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Anandamide amidohydrolase inhibitor

  35. paraffin hard

    Development asset linked to Biogen in public FDA and regional records.

  36. peginterferon beta-1a

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  37. placebo

    Development asset linked to Biogen in public FDA and regional records.

  38. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  39. saline

    Development asset linked to Biogen in public FDA and regional records.

  40. solution

    Development asset linked to Biogen in public FDA and regional records.

  41. standard

    Development asset linked to Biogen in public FDA and regional records.

  42. tablet

    Development asset linked to Biogen in public FDA and regional records.

  43. tablets

    Development asset linked to Biogen in public FDA and regional records.

  44. tofersen

    Nervous system (N07)

    US regulatory status: approved. Molecular target: SOD1 mRNA.

    Target
    SOD1 mRNA
    Mechanism
    SOD1 mRNA inhibitor

  45. treatment

    Development asset linked to Biogen in public FDA and regional records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.